Tenet Healthcare Stock: It CRUSHED Q2 and Raised Guidance — Is There Value Left?

Tenet Healthcare (THC) Q2 2026 — Tenet Healthcare (THC), the Dallas hospital + ambulatory-surgery operator, delivered a blowout Q2 2026 and RAISED full-year guidance — and the stock jumped ~17% to ~$233. Adjusted diluted EPS of $6.12 (+52% YoY vs $4.02) crushed the $4.26 estimate, on revenue of $5.63B (+6.8%) and adjusted EBITDA of $1.30B (+16%), with the adjusted EBITDA margin EXPANDING from 21.3% to 23.2%. The USPI ambulatory-surgery segment (the largest ASC operator in the U.S.) grew adjusted EBITDA 9% to $542M at a 39% margin, with same-facility revenue +5% and total-joint-replacement volumes +10%. Management raised FY2026 adjusted EPS guidance to $20.30–$21.69 (from ~$17.85), adjusted EBITDA to $4.83–$5.03B (+$295M midpoint), revenue to $21.9–$22.5B, and adjusted FCF ~$225M. Tenet has deleveraged to ~2.2x net debt/EBITDA (~$11B net debt), repurchased $1.04B of stock in Q2, and expanded its buyback authorization by $2.0B (~$2.13B remaining). The quarter was partly flattered by non-recurring prior-year Medicaid supplemental payments and contract-termination revenue, and an ACA-subsidy/payer-mix headwind looms into 2026-27. Our owner-earnings DCF + segment sum-of-parts lands fair value near $250 vs ~$233. Our call: BUY, 3/5 — the transformation is real, but much of the beat-and-raise is now priced in. Tenet Healthcare (THC) is a ~$20B Dallas-based operator of ~50 acute-care hospitals, the Conifer revenue-cycle business, and — the crown jewel — USPI (United Surgical Partners), the largest ambulatory-surgery-center operator in America with ~500 centers, led by CEO Dr. Saum Sutaria. The story is a deliberate transformation: Tenet sold dozens of hospitals and reinvested the proceeds into high-margin surgery centers and debt paydown, morphing from a leveraged hospital chain into an ambulatory-surgery compounder. Q2 2026 was a blowout beat-and-raise: adjusted diluted EPS of $6.12 (+52% YoY) crushed the $4.26 estimate, revenue rose 6.8% to $5.63B, and adjusted EBITDA jumped 16% to $1.30B — with the margin EXPANDING from 21.3% to 23.2%. USPI grew adjusted EBITDA 9% to $542M at a 39% margin (same-facility revenue +5%, total-joint volumes +10%). Management RAISED full-year guidance across the board: adjusted EPS to $20.30–$21.69 (from ~$17.85), adjusted EBITDA to $4.83–$5.03B (+$295M at the midpoint), revenue to $21.9–$22.5B, and adjusted free cash flow by ~$225M. Deleveraging (to ~2.2x net debt/EBITDA, ~$11B net debt) has unlocked aggressive capital returns — $1.04B repurchased in Q2 and a $2.0B buyback-authorization expansion (~$2.13B remaining) on a share count down to ~84M. The honest catch: the quarter was partly flattered by non-recurring prior-year Medicaid supplemental payments and one-time contract-termination revenue, and an ACA enhanced-subsidy expiration / payer-mix cliff is a real headwind into 2026-27. The stock had already round-tripped ($148 low → $245 high → ~$179 in June) before exploding ~17% to ~$233 on the print, back near its 52-week high. Our owner-earnings DCF (9/10/11%) plus a USPI-vs-hospitals segment sum-of-parts lands fair value near $250 — modestly above the price — with the buyback adding a per-share tailwind. Our call: BUY, 3/5 — a deleveraged ambulatory compounder where the transformation is genuine, but much of the beat-and-raise is now priced in. Wall Street is a Buy (26 buy / 6 hold) with a ~$255 average target, though the freshest post-print targets (Wells Fargo $231, BofA $230, Barclays $240, Guggenheim $242) cluster right at today's price. Add on the pullbacks it keeps handing you, and watch USPI volumes and the payer mix. Not financial advice. THE CALL: BUY (3/5, A DELEVERAGED AMBULATORY COMPOUNDER — A BEAT-AND-RAISE, WITH MUCH NOW PRICED IN) — base-case value ~$250 vs ~$233 today. What to watch: evidence the USPI ambulatory-surgery flywheel keeps outrunning the payer-mix drag — USPI becoming an ever-larger share of EBITDA at ~39% margins, continued deleveraging, and the buyback rolling on — which would justify an upgrade toward 4/5; the risk to respect is the ACA enhanced-subsidy expiration / payer-mix and Medicaid-supplemental headwind biting harder than guided into 2026-27, or the one-time items (prior-year Medicaid supplemental payments, contract-termination revenue) proving to have masked a weaker underlying trend near a 52-week-high price Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.